^（131）I标记抗肝癌单克隆抗体HAb18生物动力学及器官吸收剂量  

Biokinetics and dose estimation from 131 I labeled monoclonal anti hepatocellular carcinoma antibody HAb18

作　　者：张裕民[1,2] 邓敬兰[1,2] 陈敏[1,2] 张新睿[1,2] 乔宏庆 何凤昌[1,2] 陈志南 

机构地区：[1]第四军医大学西京医院核医学科 [2]第四军医大学病理学教研室

出　　处：《第四军医大学学报》1996年第4期254-257,共4页Journal of the Fourth Military Medical University

摘　　要：目的：考察１３１Ｉ－ＨＡｂ１８在正常人体内的生物学分布和器官辐射吸收剂量，为临床应用提供必需的依据。方法：一健康志愿者静脉给药后不同时间用Ｙ相机行全身及局部显像，并采取血样本及留全尿，按医学内照射剂量（ＭＩＲＤ）纲要计算器吸收剂量。结果：给药后１，４，２４，４８，７２，９６及１２０ｈ显像示血池，肝脏内放射性呈持续高水平，外生殖器及甲状腺亦显影。血中放射性持续清除，主要经肾由尿中排泄，给药后２４ｈ及４８ｈ分别排除给药量的２８．２％及６４．８％。器官吸收剂量（ｍＧＹ／ＭＢｑ）分别为：全身０．１８４，肝０．３６，甲状腺３．５７，睾丸１．８１。有效剂量当量（ＥＤＥ）为０．９５８ｍＳｖ／ＭＢｑ，受试者生命征无改变。结论：１３１Ｉ－ＨＡｂ１８用于人体是安全的，但应注意封闭甲状腺。Objective: The normal biokinetics of 131 I labeled monoclonal anti hepatocellular carcinoma (HCC) antibody HAb18 ( 131 I HAb18) was obtained and its radiation dose was calculated in a volunteer to provide essential data for clinical application of the HCC seeking agent. Methods: Serial whole body and static scintigraphic images were taken, and blood and urine samples were collected. The radiation absorbed doses to the organs were calculated according to the MIRD concept. Results: The scintigraphic images at 1, 4, 24, 48, 72, 96 and 120 hours post injection (p.i.) demonstrated a prolonged activity retention in the blood pool and high activity in the liver. The thyroid and genitals uptake was also visualized. The activity in the blood disappeared continually and excreted via urine. 28.2% and 64% of the administered activity was excreted in urine within 24 and 72 hours p.i.. The calculated organ absorbed doses, all in mGy/MBq, were as follows: whole body 0.184, liver 0.36, thyroid 3.57, testes 1.81. Effective dose equivalent was 0.958 mSv/MBq. No changes in vital signs were observed after administration of 131 I HAb18. Conclusion: Low radiation dose of 131 I HAb18 is acceptable and the radiopharmaceutical is a safe agent for detecting HCC.

关 键 词：单克隆抗体 肝肿瘤 生物动力学 吸收剂量 碘131 

分 类 号：R735.704[医药卫生—肿瘤]